Sugi Predict

Sugi Predict / Compounds / SCHEMBL1607703

SCHEMBL1607703

SCHEMBL1607703

O=Cc1ccccc1OCCBr

nearest known ligand 0.77

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 6/20 0.77
▸ HPGD P15428 1/20 0.77
▸ HTT P42858 1/20 0.77
▸ SMN1; SMN2 Q16637 1/20 0.77
▸ PTGDR2 Q9Y5Y4 1/20 0.58
▸ MAPT P10636 2/20 0.51
▸ KMT2A Q03164 5/20 0.50
▸ LMNA P02545 3/20 0.50
▸ GAA P10253 1/20 0.50
▸ MEN1 O00255 3/20 0.49
▸ SRC P12931 2/20 0.47
▸ TDP1 Q9NUW8 2/20 0.46
▸ BLM P54132 2/20 0.46
▸ THRB P10828 1/20 0.46
▸ KDM4E B2RXH2 1/20 0.45
▸ POLB P06746 1/20 0.45
▸ RECQL P46063 1/20 0.45
▸ L3MBTL1 Q9Y468 1/20 0.45
▸ RAD52 P43351 1/20 0.44
▸ CYP1A2 P05177 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7908486 0.90 ALDH1A1 (0.74) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL31603832 0.89 ALDH1A1 (0.72) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL7903822 0.89 ALDH1A1 (0.71) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL6914412 0.87 ALDH1A1 (1.00) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL19328388 0.87 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL28518730 0.87 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL10482275 0.87 ALDH1A1 (0.69) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL7714714 0.86 ALDH1A1 (0.73) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL8372730 0.85 ALDH1A1 (0.87) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2
SCHEMBL5805320 0.85 ALDH1A1 (0.87) ALDH1A1HPGDHTTSMN1; SMN2PTGDR2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116969904-A Compounds useful as autophagy modulators, methods of preparation and uses thereof 微境生物医药科技(上海)有限公司 2023-10-31 — — CN disclosed
CN-111148740-B Compounds useful as autophagy modulators, methods of preparation and uses thereof 微境生物医药科技(上海)有限公司 2023-08-25 — — CN disclosed
CN-115232319-A Supermolecule polyaldehyde compound based on poly-beta-cyclodextrin and ferrocene host-guest action and preparation method thereof 四川大学 2022-10-25 — — CN disclosed
CN-115160454-A Supermolecule polyaldehyde compound based on poly-beta-cyclodextrin and adamantane host-guest action and preparation method thereof 四川大学 2022-10-11 — — CN disclosed
EP-2265590-B1 SELECTIVE INHIBITORS OF HISTONE DEACETYLASE PHARMACYCLICS LLC (US) 2016-04-13 — — EP disclosed
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE PHARMACYCLICS LLC 2015-11-12 — — US disclosed
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE PHARMACYCLICS LLC 2015-11-12 — — US disclosed
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE PHARMACYCLICS LLC 2015-11-12 — — US disclosed
US-8906954-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2014-12-09 — — US disclosed
US-8906954-B2 Selective inhibitors of histone deacetylase PHARMACYCLICS, INC. (US) 2014-12-09 — — US disclosed
EP-0897540-B1 METHOD FOR DETECTING AND/OR QUANTIFYING A HAPTEN IN A HOMOGENEOUS PHASE AND DEVICE FOR IMPLEMENTATION THEREOF WALLONE REGION (BE) 2001-07-04 — — EP disclosed
US-6191152-B1 CARDIOVASCULAR DISORDERS, NERVOUS SYSTEM DISORDERS EGIS GYÓGYSZERGYAR RT. (HU) 2001-02-20 — — US disclosed
EP-0958294-A1 2-(1,2,4-TRIAZOLE-1-YL)-1,3,4-THIADIAZOLE DERIVATIVES HAVING AN EFFECT ON THE C.N.S. AND THE HEART EGIS GYOGYSZERGYAR (HU) 1999-11-24 — — EP disclosed
US-5889032-A Heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-03-30 — — US disclosed
US-5885997-A Heterocyclic compounds, process for their preparation and pharmaceutical compositions containing them and their use in the treatment of diabetes and related diseases DR. REDDY'S RESEARCH FOUNDATION (IN) 1999-03-23 — — US disclosed
EP-0897540-A1 METHOD FOR DETECTING AND/OR QUANTIFYING A HAPTEN IN A HOMOGENEOUS PHASE AND DEVICE FOR IMPLEMENTATION THEREOF LA REGION WALLONNE (BE) 1999-02-24 — — EP disclosed
WO-1998030561-A1 2-(1,2,4-TRIAZOLE-1-YL)-1,3,4-THIADIAZOLE DERIVATIVES HAVING AN EFFECT ON THE C.N.S. AND THE HEART EGIS Gyógyszergyár Rt. (HU) 1998-07-16 — — WO disclosed
WO-1997041435-A1 METHOD FOR DETECTING AND/OR QUANTIFYING A HAPTEN IN A HOMOGENEOUS PHASE AND DEVICE FOR IMPLEMENTATION THEREOF LA REGION WALLONNE (BE) 1997-11-06 — — WO disclosed
EP-0058890-B1 ANTITHROMBOTIC COMPOUNDS THE WELLCOME FOUNDATION LIMITED (GB) 1984-09-26 — — EP disclosed
EP-0058890-A1 Antithrombotic compounds THE WELLCOME FOUNDATION LIMITED (GB) 1982-09-01 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150320758-A1 SELECTIVE INHIBITORS OF HISTONE DEACTYLASE HDAC8, HDAC1, HDAC5 ALDH1A1 1970/4885HPGD 1537/4885HTT 290/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.